An agonist antibody prefers relapsed AML for induction of cells that kill each other
| Autor: | Minseok Kim, Yong-Seok Oh, Hongkai Zhang, Sanghee Shin, Kyungmoo Yea, Dokyung Jung, Richard A. Lerner, Teresa M. Jones, Kyung Ho Han, Zhao Zha, Britni M. Arlian |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Agonist medicine.drug_class Transplantation Heterologous Population lcsh:Medicine Mice SCID Antibodies Article Mice 03 medical and health sciences 0302 clinical medicine Mice Inbred NOD Recurrence Cell Line Tumor hemic and lymphatic diseases Animals Humans Medicine Cytotoxic T cell lcsh:Science education neoplasms Thrombopoietin receptor education.field_of_study Multidisciplinary biology business.industry lcsh:R Recombinant Proteins Killer Cells Natural Granzyme B Leukemia Myeloid Acute 030104 developmental biology Thrombopoietin Perforin Cancer research biology.protein lcsh:Q Antibody business Cytokine receptor Receptors Thrombopoietin 030217 neurology & neurosurgery Signal Transduction |
| Zdroj: | Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | Previously, we reported an agonist antibody to a cytokine receptor, Thrombopoietin receptor (TPOR) that effectively induces cytotoxic killer cells from precursor tumor cells isolated from newly diagnosed AML patients. Here, we show that the TPOR agonist antibody can induce even relapsed AML cells into killer cells more potently than newly diagnosed AML cells. After stimulation by the agonist antibody, these relapsed leukemic cells enter into a differentiation process of killer cells. The antibody-induced killer cells express, Granzyme B and Perforin that assault and kill other members of the AML cell population. Particularly, the agonist antibody showed potent efficacy on the AML xenograft model in mice using the NOD/LtSz-scid IL2Rγc null (NSG) mice. These results show that the TPOR agonist antibody that induces AML cells to kill each other is effective on both relapsed AML cells and in vivo. Therefore, this study suggests a new strategy for the treatment of cancer relapse after chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|